OncoPharm

Cytarabine, the 'c' chemotherapy from the sea, is discussed.

Recent FDA updates are discussed including combined use of BRAF & MEK inhibitors, frontline daratumumab (10:20), and your next P & T monograph drug to review.

Dive into the fascinating journey of methotrexate, from its origins as an antifolate to a cornerstone in chemotherapy. Discover its mechanisms, dosing intricacies, and safety measures vital for treating acute lymphoblastic leukemia and other conditions. This exploration highlights how this once-simple drug has evolved into a crucial player in modern oncology, showcasing its lasting impact on patient care.

Recent FDA & #oncopharm updates are discussed, including irinotecan in sweat, fostamatinib's FDA-approval for ITP. Then, immunotherapy updates from AACR are reviewed (6:00). Finally (34:00 , osimertinib's updated approval for frontline use in mEGFR NSCLC.

You've heard of NSABP, but have you heard of adjuvant melphalan, 5-FU, & concurrent tamoxifen? Sometimes asking the right question yields answers we don't yet understand.

The Foundations in Oncology Pharmacy continues with vincristine. Its origin, unique toxicity profile, and clinical use is discussed. Periwinkle!

Highlights from last week's HOPA annual conference are discussed, followed by (13:09) a lightning-style run through of #oncopharm updates over the last 2 weeks.

Previewing HOPA18 and its highly anticipated sessions, networking opportunities, and virtual attendance.

PVB's (cisplatin, vinblastine, bleomycin) impressive cure rate for testicular cancer is 1977 is discussed. Then the evolution of the BEP & EP regimen is summarized.

Abemaciclib's up-front approval provides an opportunity to review all 3 currently FDA-approved CDK 4/6 inhibitors. Dosing, drug interaction, and indication differences are discussed.